Basel, Switzerland, July 13th, 2018
EsoCap AG announced that it has successfully completed a private placement financing round on July 13th, 2018. The proceeds of the capital increase will be used toward the completion of the technical development of EsoCap’s unique drug delivery technology and the initiation of a clinical proof-of-concept trial in eosinophilic esophagitis (EoE).
”We are delighted to have secured the financial resources to continue our fast paced development program,” said Isabelle Racamier, CEO of EsoCap. “This financing allows EsoCap to finalize the technical development of its unique topical drug delivery platform for diseases of the upper gastrointestinal tract. The company is now in a position to rapidly advance its innovative technology toward the clinic.”
The private financing round includes investments from existing as well as from new investors with a strong entrepreneurial and scientific background. This funding is instrumental as it provides a solid bridge to clinical development.
